Higher metabolic risk in Chinese women fulfilling the NIH diagnostic criteria for polycystic ovarian syndrome

Higher Metabolic Risk with National Institutes of Health Versus Rotterdam Diagnostic Criteria for Polycystic Ovarian Syndrome in Turkish Women

“…In the present study, 69% of the 175 women diagnosed with PCOS according to the Rotterdam criteria also met the 1990 NIH criteria, similar to the 55%-70% reported in other cohorts. [17][18][19]21,23 In contrast, a study from Hong Kong showed the prevalence of PCOS to be 96% based on the Rotterdam criteria. 15 Ethnicity is known to be an important predictor of the prevalence and metabolic determinants of PCOS.…”

“…18 Our study findings are in agreement with these reports, and other studies have revealed that the NIH criteria are better able to detect metabolic abnormalities in women with PCOS. [19][20][21][22][23] …”

“…In phenotype. 12,[15][16][17][18][19][20][21][22][23] We compared the clinical, endocrine, and metabolic features of: (1) Women with PCOS according to the NIH criteria, (2) those with PCOS by the Rotterdam criteria, (3) ovulatory women with idiopathic hirsutism, and (4) healthy, nonhirsute, ovulatory women.…”

Dysregulation of glucose metabolism even in Chinese PCOS women with normal glucose tolerance

“…It is important to prevent glucose metabolic disorder of PCOS as early as possible since more than 40% of PCOS women might develop impaired glucose tolerance or type 2 diabetes [2,3]. However, the early interventions of improving glucose metabolism were seldom adopted because the glucose levels of PCOS women were normal before developing impaired glucose tolerance.…”

The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome—a double-blind randomized placebo-controlled study

“…However, only three of these studies were randomized placebo-controlled trials and they were limited to the Caucasian population (8,9,11). Recent studies on the Chinese population with PCOS have demonstrated a high prevalence of metabolic syndrome and cardiovascular risk factors, and this suggests that there is a potential ethnic variation in the clinical manifestation and also possibly a different response to treatment (12)(13)(14). The aim of this randomized double-blind placebo-controlled study is to assess the effects of rosiglitazone on a number of important clinical and biochemical parameters of PCOS in Chinese women.…”